Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

For years, people with diabetes have sought out an accurate way to measure glucose without the need for fingersticks or fluid samples. Here’s a look at the latest in research and development of non-invasive glucose monitoring devices. Continue Reading »

Time in Range (TIR) is a well established and easy to use measurement of your daily glucose management. The glycemia risk index (or dysglycemia index) is an emerging measurement, currently being researched, that combines seven of your CGM metrics, including TIR, into a numeric score that your healthcare provider can use to quickly identify areas for adjustments within your glucose management. Continue Reading »

How can you prevent or slow the progression of diabetic neuropathy with a continuous glucose monitor (CGM)? Research shows that higher Time in Range (TIR) is associated with a lower risk of nerve damage in people with diabetes. Continue Reading »

Exciting new developments in diabetes research show that increasing your Time in Range can lower your risk of developing heart complications. Continue Reading »

A follow up to the MOBILE study, which demonstrated improvements in A1C and Time in Range for continuous glucose monitoring system (CGM) users with type 2 diabetes, shows that discontinuing CGM can erase these improvements.  Continue Reading »

The hope of a cure for type 1 diabetes has long eluded scientific discovery. When Vertex Pharmaceuticals announced positive data from its first clinical trial participant, it’s possible we got a little closer to our goal. Continue Reading »

Heart failure is one of the most common diabetes complications. New results from the EMPEROR-Preserved clinical trial show that Jardiance could be the first medication shown to help all people with heart failure. Continue Reading »

If you are currently taking three or more insulin injections per day, you may be eligible to participate in a clinical trial that provides you with the Guardian Connect continuous glucose monitor (CGM) system, InPen smart insulin pen, and smart insulin pen caps. Continue Reading »

Pages